Heron Therapeutics | HRTX - Betriebsaufwand

Aktienkurs
0.78
Täglich Wechseln
-0.04 -4.74%
Monatlich
-34.57%
Jährlich
-67.29%
Q1 Prognose
0.76




Betriebsaufwand Veränderung Datum
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 217.93M 287.88M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Esperion Therapeutics USD 83.21M 14.06M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 577.6M 22M 2025-12
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 193.68M 27.32M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Surmodics USD -245.35M 363.49M 2024-09
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Veracyte USD 116M 7.24M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12